CHANGES IN THE FUNCTIONAL ACTIVITY OF MACROPHAGES UNDER THE INFLUENCE OF BACTERIAL LECTIN APPLAIED IN DIFFERENT SCHEMES
DOI:
https://doi.org/10.15407/oncology.2023.01.032Keywords:
карцинома легені Льюїс, лектин B. subtilis IМВ B7724, М1 та М2 поляризація, макрофаги, функціональна активність, цисплатинAbstract
Aim: to investigate the antitumor effect and the influence of B. subtilis IMV B-7724 lectin applied as a single therapy or in combination with cisplatin on various manifestations of macrophages functional activity during the growth of a metastasizing experimental tumor. Materials and methods: the study was performed on C57Bl/6J mice bearing Lewis lung carcinoma (LLC). The effect of the lectin applied as a single therapy or in combination with cisplatin on tumor growth and the functional activity of peritoneal macrophages were evaluated. The functional activity of peritoneal macrophages was studied by the level of NO production, arginase and cytotoxic activity. Results: there was demonstrated an antimetastatic efficacy of B. subtilis IMV B-7724 lectin applied in Lewis lung carcinoma model either as a single therapy or in combination with cisplatin. In all probability, this effect was grounded by the changes in macrophages functional activity. As it is evidenced by a significant (p < 0.05) suppression of macrophages’ cytotoxic activity and characteristic changes in arginase metabolism, M2 macrophages predominated in the control (untreated) tumor-bearing mice. The features of L-arginine metabolism and cytotoxic activity in peritoneal macrophages indicate the preservation of their antitumor activity (polarization toward M1 type) at the terminal stage of experimental tumor growth. Conclusions: in the animals bearing experimental tumor, the most pronounced antitumor effect was observed when the bacterial lectin was applied in combination with cisplatin. The use of B. subtilis IMV B-7724 lectin as a therapeutic agent (either as a single therapy or in combination with cisplatin) preserved the antitumor activity of macrophages and promoted their polarization toward M1 direction at the terminal stage of tumor growth.
References
Baxter-Holland M, Dass CR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. J Pharm Pharmacol 2018; 70 (3): 320–7.
Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 2018; 419: 210–221. doi: 10.1016/j.canlet.2018.01.050.
Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28 (6): 690–714. doi: 10.1016/j.ccell.2015.10.012.
Rodrigues MC, Morais JAV, Ganassin R, et al. An overview on immunogenic cell death in cancer biology and therapy. Pharmaceutics 2022; 14 (8): 1564. doi: 10.3390/pharmaceutics14081564.
Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120 (4): 1111–24. doi: 10.1172/JCI40269.
Zhang L, Zhou C, Zhang S, et al. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol 2022; 12: 939249. doi: 10.3389/fonc.2022.939249.
Merlano MC, Denaro N, Galizia D, et al. How chemotherapy affects the tumor immune microenvironment: a narrative review. Biomedicines 2022; 10 (8): 1822. doi: 10.3390/biomedicines10081822.
Zheng X, Mansouri S, Krager A, et al. Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment. Eur Respir Rev 2020; 29 (157): 200134. doi: 10.1183/16000617.0134-2020.
Xu Y, Wang X, Liu L, et al. Role of macrophages in tumor progression and therapy (Review). Int J Oncol 2022; 60 (5): 57. doi: 10.3892/ijo.2022.5347.
Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol 2019; 12 (1):76. doi: 10.1186/s13045-019-0760-3.
Jackute J, Zemaitis M, Pranys D, et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol 2018; 19 (1): 3. doi: 10.1186/s12865-018-0241-4.
Wei X, Nie S, Liu H, et al. Angiopoietin-like protein 2 facilitates non-small cell lung cancer progression by promoting the polarization of M2 tumor-associated macrophages. Am J Cancer Res 2017; 7 (11): 2220–33.
Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 2016; 27 (8): 1482–92. doi: 10.1093/annonc/mdw168.
Kozhemyakin YM, Khromov OS, Filonenko MA, Sayfutdinova HA. Guideline on management of laboratory animals and work with them. Kyiv: Avitsena 2002; 179 p. (in Ukrainian)
Kellar A, Egan C, Morris D. preclinical murine models for lung cancer: clinical trial applications. Biomed Res Int 2015; 2015: 621324. doi: 10.1155/2015/621324.
Fedosova NI, Cheremshenko NL, Hetman KI, et al. Physicochemical and cytotoxicity properties of Bacillus subtilis ІМV В-7724 extracellular lectin. Mikrobiol Z 2021; 83 (1): 39–48. https://doi.org/10.15407/microbiolj83.01.039.
Reiner NE. Methods in molecular biology. Macrophages and dendritic cells. Methods and protocols. Preface. Methods Mol Biol 2009; 531: v-vi. doi: 10.1007/978-1-59745-396-7.
Van de Loosdrecht AA BR, Ossenkoppele GJ. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Met 1994; 174 (1–2): 311–20.
Chumak AV, Fedosova NI, Cheremshenko NL, et al. Macrophage polarization in dynamics of Lewis lung carcinoma growth and metastasis. Exp Oncol 2021; 43 (1): 15–20. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.15829.
Redente EF, Dwyer-Nield LD, Merrick DT, et al. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 2010; 176 (6): 2972–85. doi: 10.2353/ajpath.2010.090879.
Sumitomo R, Hirai T, Fujita M, et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer. Exp Ther Med 2019; 18 (6): 4490–8. doi: 10.3892/etm.2019.8068.
Cao L, Che X, Qiu X, et al. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cancer Manag Res 2019;11: 6125–38. doi: 10.2147/CMAR.S199832.
Mei J, Xiao Z, Guo C, et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: a systemic review and meta-analysis. Oncotarget 2016; 7 (23): 34217–28. doi: 10.18632/oncotarget.9079.
